<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01178320</url>
  </required_header>
  <id_info>
    <org_study_id>627</org_study_id>
    <secondary_id>R01HL088214</secondary_id>
    <nct_id>NCT01178320</nct_id>
  </id_info>
  <brief_title>Carotid Plaque Characteristics by MRI in AIM-HIGH (Carotid MRI Substudy)</brief_title>
  <official_title>Carotid Plaque Characteristics by MRI in AIM-HIGH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart attacks and strokes caused by the unstable atherosclerotic plaques remain the leading
      cause of death in the United States. Unstable plaques often have more fat than stable
      plaques. This study will investigate if a treatment with LDL-lowering plus HDL-raising
      compared with LDL-lowering alone would more effectively reduce the plaque fat content
      assessed by magnetic resonance imaging (MRI), therefore, further reducing heart attacks and
      strokes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although studies have suggested that plaque morphology and composition are important
      determinants of plaque stability, our understanding on plaque tissue components is mainly
      from histological studies until recent development in MRI technique. A low level of HDL is
      associated with higher risk of cardiovascular events and increased amount of lipid content in
      the carotid plaques. Treatment with LDL-lowering plus HDL-raising compared with LDL-lowering
      alone more effectively protects against atherosclerosis progression. It is widely believed
      that HDL or its apolipoproteins mediate the removal of excess free cholesterol from
      peripheral cells and the cholesterol is delivered via either LDL or HDL to the liver for
      excretion into the bile. However, it has not been tested and approved in human
      atherosclerotic condition in vivo. The NIH/Abbott-funded multi-center AIM-HIGH trial is
      designed to compare the clinical efficacy of LDL-lowering alone with statin versus
      LDL-lowering plus HDL-raising with statin plus nicotinic acid combination therapy in patients
      with established vascular disease and high triglycerides and low HDL.

      We propose to conduct a carotid MRI sub-study in 220 subjects enrolled in AIM-HIGH to
      investigate the important vascular biological mechanisms of HDL-raising therapy. Image
      collection will occur at 3 timepoints. The hypotheses and specific aims are:

        -  (1) To test the primary hypothesis that compared with LDL-lowering alone, intensive
           LDL-lowering plus HDL-raising therapy decreases the mean plaque lipid composition in
           carotid arteries assessed by MRI.

        -  (2) To test the hypothesis that compared with LDL-lowering alone, intensive LDL-lowering
           plus HDL-raising therapy decreases the plaque burden including volume and wall
           thickness.

        -  (3) To test the hypothesis that increased plaque lipid composition or vessel wall
           thickness by MRI is associated with increased risk of cardiovascular events.

        -  (4)To test a hypothesis that LDL-lowering plus HDL-raising, compared to LDL-lowering
           alone, will promote more rapid plaque lipid depletion. And determine the time-course of
           atherosclerotic plaque lipid depletion during lipid therapy.

        -  (5) To examine the association of clinical risk factors, lipids, lipoprotein
           heterogeneity, inflammatory markers and carotid plaque characteristics.

      This MRI sub-study offers a unique opportunity to investigate the effectiveness of
      LDL-lowering plus HDL-raising therapy on human atherosclerotic plaque in vivo, to examine the
      association of plaque characteristics both lipid composition and volume assessed by MRI and
      cardiovascular outcome, and to gain novel insights in our understanding of atherosclerotic
      plaque pathology and the mechanisms of intensive lipid management in preventing
      cardiovascular events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean plaque lipid composition in carotid arteries assessed by MR</measure>
    <time_frame>Through 24Months post AIM-HIGH Randomization</time_frame>
    <description>To test the primary hypothesis that compared with LDL-lowering alone, intensive LDL-lowering plus HDL-raising therapy decreases the mean plaque lipid composition in carotid arteries assessed by MRI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Additional plaque characteristics as assessed by MRI</measure>
    <time_frame>Through 24Months post AIM-HIGH Randomization</time_frame>
    <description>To test the additional hypotheses regarding plaque burden, plaque lipid depletion time course, association with cardiovascular event risk and lipid characteristics.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">230</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Carotid Artery Diseases</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <description>Participants in the main AIM-HIGH study who are receiving simvastatin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin and Extended-Release Niacin</arm_group_label>
    <description>Participants in the main AIM-HIGH study who are receiving simvastatin and extended-release niacin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin, simvastatin plus extended-release niacin</intervention_name>
    <description>Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.</description>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_label>Simvastatin and Extended-Release Niacin</arm_group_label>
    <other_name>simvastatin</other_name>
    <other_name>Zocor</other_name>
    <other_name>niacin</other_name>
    <other_name>Niaspan</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants in the main AIM-HIGH study (NCT00120289)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible for main AIM-HIGH study (NCT00120289)

          -  Medically able to undergo MRI procedure

          -  Willing to provide informed consent for participation in this substudy

        Exclusion Criteria:

          -  Uses pacemaker or has metallic implants

          -  History of bilateral carotid endarterectomy

          -  Glomerular filtration rate less than 60 mL/min/1.73 m^2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xue-Qiao Zhao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiovascular Consultants</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach VA Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia VA Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kelsey Research Foundation</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puget Sound VA Medical Center, Seattle Campus</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Health Institute</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2E-7C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N-2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z-1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Western Ontario</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A-5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hippe DS, Phan BAP, Sun J, Isquith DA, O'Brien KD, Crouse JR, Anderson T, Huston J, Marcovina SM, Hatsukami TS, Yuan C, Zhao XQ. Lp(a) (Lipoprotein(a)) Levels Predict Progression of Carotid Atherosclerosis in Subjects With Atherosclerotic Cardiovascular Disease on Intensive Lipid Therapy: An Analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) Carotid Magnetic Resonance Imaging Substudy-Brief Report. Arterioscler Thromb Vasc Biol. 2018 Mar;38(3):673-678. doi: 10.1161/ATVBAHA.117.310368. Epub 2018 Jan 4.</citation>
    <PMID>29301785</PMID>
  </results_reference>
  <results_reference>
    <citation>Sun J, Zhao XQ, Balu N, Hippe DS, Hatsukami TS, Isquith DA, Yamada K, Neradilek MB, Cant√≥n G, Xue Y, Fleg JL, Desvigne-Nickens P, Klimas MT, Padley RJ, Vassileva MT, Wyman BT, Yuan C. Carotid magnetic resonance imaging for monitoring atherosclerotic plaque progression: a multicenter reproducibility study. Int J Cardiovasc Imaging. 2015 Jan;31(1):95-103. doi: 10.1007/s10554-014-0532-7. Epub 2014 Sep 13.</citation>
    <PMID>25216871</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen H, Sun J, Kerwin WS, Balu N, Neradilek MB, Hippe DS, Isquith D, Xue Y, Yamada K, Peck S, Yuan C, O'Brien KD, Zhao XQ. Scan-rescan reproducibility of quantitative assessment of inflammatory carotid atherosclerotic plaque using dynamic contrast-enhanced 3T CMR in a multi-center study. J Cardiovasc Magn Reson. 2014 Aug 1;16:51. doi: 10.1186/s12968-014-0051-7.</citation>
    <PMID>25084698</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhao XQ, Hatsukami TS, Hippe DS, Sun J, Balu N, Isquith DA, Crouse JR 3rd, Anderson T, Huston J 3rd, Polissar N, O'Brien K, Yuan C; AIM-HIGH Carotid MRI Sub-study Investigators. Clinical factors associated with high-risk carotid plaque features as assessed by magnetic resonance imaging in patients with established vascular disease (from the AIM-HIGH Study). Am J Cardiol. 2014 Nov 1;114(9):1412-9. doi: 10.1016/j.amjcard.2014.08.001. Epub 2014 Aug 13.</citation>
    <PMID>25245415</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2010</study_first_submitted>
  <study_first_submitted_qc>August 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2010</study_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Xue-Qiao Zhao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>Atherosclerotic Plaque</keyword>
  <keyword>Lipid Lowering Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Carotid Artery Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

